01Core principlesThe concepts and mechanisms needed to understand the subject.
Receptor testing converts morphology into actionable tumour biology. ER and PR immunohistochemistry detect nuclear expression of steroid-hormone receptors; ER is the central marker for endocrine sensitivity, while PR adds biological and prognostic context. HER2 assessment identifies protein overexpression or gene amplification driving proliferative signalling. A pathology report must identify the specimen and method so results are attached to the correct invasive tumour rather than an adjacent in-situ component.
Simultaneous initial testing prevents sequential delays between diagnosis, multidisciplinary review and systemic planning. A positive receptor is a treatment opportunity, not a complete treatment prescription. Endocrine therapy is selected according to menopausal state and risk; HER2-directed therapy requires assessment of indication and cardiac safety; cytotoxic therapy depends on stage and biology. When disease recurs, reassessment is useful if genuine biological change or sampling difference would alter available treatment.
Key points
- NICE recommends assessing ER, PR and HER2 simultaneously at the initial histopathological diagnosis of every invasive breast cancer so results are ready for the first treatment discussion.
- ER and PR are nuclear hormone receptors. Positivity supports potential benefit from endocrine manipulation, but treatment choice still depends on menopausal status, recurrence risk, comorbidity and patient preference.
- HER2 overexpression or gene amplification identifies a biologically distinct group that may benefit from HER2-directed treatment; equivocal laboratory results need the validated reflex pathway, not a clinical guess.
- Triple-negative cancer lacks ER, PR and HER2 targets. It is a treatment-relevant phenotype, not a synonym for inherited BRCA disease or for one histological grade.
- Receptors can differ between a primary tumour and recurrence. NICE advises considering reassessment in recurrent disease when a changed result would alter management.
- Biomarkers predict sensitivity but do not replace staging. A small ER-positive node-negative tumour and an extensive ER-positive node-positive tumour share a target but not the same absolute recurrence risk.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Tumour nuclei demonstrate oestrogen-receptor expression on validated immunohistochemistry, supporting endocrine responsiveness but not guaranteeing that every cell or metastasis will respond.
Progesterone-receptor expression reflects an active hormone pathway and contributes biological information, while ER remains the main determinant of endocrine treatment eligibility.
Validated testing demonstrates HER2 protein overexpression or gene amplification, opening a treatment pathway that also requires regimen and cardiac assessment.
The invasive cancer lacks the three measured targets; chemotherapy, immunotherapy or other options depend on stage and current eligibility rather than the label alone.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
ER immunohistochemistry - Why
- Determine whether the invasive tumour expresses the oestrogen receptor and may benefit from endocrine treatment.
- Interpretation and limitations
- Interpret the reported proportion and laboratory category under the validated pathology method. A result must be linked to invasive tumour tissue, not inferred from morphology.
- 02
PR immunohistochemistry - Why
- Add hormone-pathway and prognostic information at the same initial diagnostic assessment.
- Interpretation and limitations
- PR can be discordant with ER. It refines biological understanding but does not substitute for ER or independently define stage.
- 03
HER2 testing with reflex resolution - Why
- Identify HER2 overexpression or amplification and resolve an equivocal initial result through the laboratory algorithm.
- Interpretation and limitations
- A clear positive supports consideration of HER2-directed treatment. Borderline wording is not a licence to start treatment before confirmatory testing is complete.
- 04
Representative repeat biopsy at recurrence - Why
- Reassess receptor biology when a new result would change systemic options and tissue can be obtained safely.
- Interpretation and limitations
- A different result may reflect evolution, heterogeneity, treatment selection or sampling. Confirm specimen identity and assay quality before changing therapy.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked case: simultaneous profilingTurn one core into a complete first decisionIllustrative worked example: a 47-year-old has a 32 mm grade 3 invasive carcinoma, a biopsy-positive ipsilateral axillary node and no distant disease on staging; the first multidisciplinary meeting is in seven days.+
- 1The team confirmed viable invasive tumour in the correctly labelled core and requested ER, PR and HER2 simultaneously at initial histopathological diagnosis.
- 2The laboratory reported ER-positive staining in 80% of invasive cells, PR-positive staining in 30%, and a HER2-positive result confirmed through its validated testing pathway. These are illustrative results; the anatomical extent remained cT2N1M0.
- 3At the meeting, the clinicians combined this biology with the node-positive extent, fitness and the patient's preferences and agreed oncology-led neoadjuvant systemic treatment with a HER2-directed component, followed by response-guided surgical planning. Endocrine treatment was retained in the subsequent plan because the tumour was ER-positive.
- 4The oncology assessment was completed, the planned cardiac assessment showed function acceptable for the proposed treatment, and consent documented both the HER2-related plan and later endocrine discussion.
- 5At the next team review, all three signed receptor results and the oncology treatment-start record were available; treatment had begun and no unresolved equivocal assay was delaying care. This observed process outcome shows why parallel profiling mattered without claiming receptors alone determined the whole plan.
02Equivocal HER2 pathwayResolve the laboratory uncertaintyThe report states that HER2 immunohistochemistry is equivocal and no gene result is yet available.+
- 1Do not relabel the cancer HER2-positive or HER2-negative from the equivocal line alone.
- 2Ask pathology to complete the validated reflex test and confirm adequate invasive tumour and internal controls.
- 3Plan the treatment discussion using established clinical information while marking HER2-dependent choices as pending.
- 4Review and document the final integrated result before prescribing a HER2-directed medicine.
03Recurrent disease pathwayRetest when the answer can change careA patient previously had ER-positive, HER2-negative cancer and now has a safely accessible liver lesion at first metastatic recurrence.+
- 1Confirm imaging is compatible with metastatic disease and decide whether biopsy can distinguish recurrence from a new primary or benign lesion.
- 2Obtain representative tissue and request relevant receptors when the result will change systemic therapy.
- 3Compare new and original pathology, considering heterogeneity, technical quality and interval treatment rather than treating discordance as clerical error.
- 4Select therapy from the confirmed current phenotype, disease burden, organ function and patient goals, then verify early response and toxicity.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Track ER, PR and final HER2 status as discrete results and do not mark profiling complete while an equivocal HER2 assay remains unresolved.
- Before systemic therapy, verify specimen identity, invasive histology, stage, menopausal status and relevant comorbidities in the multidisciplinary plan.
- For HER2-directed treatment, complete the regimen-specific baseline and interval cardiac monitoring required by the selected medicine and oncology protocol.
- At recurrence, record whether repeat biopsy was feasible, whether receptors were reassessed and exactly how any discordance changed the treatment recommendation.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Predictive is not deterministic
ER or HER2 positivity increases the chance of benefit from a matching therapy; it does not promise response or quantify baseline recurrence risk.
Simultaneous testing saves clinical time
Parallel ER, PR and HER2 assessment lets the first preoperative meeting consider all main biological pathways instead of serially postponing decisions.
Stage and biology answer different questions
Anatomical stage estimates where cancer has spread; receptor status identifies cellular dependencies that can be targeted within that stage.
Recurrence can differ
Tumour heterogeneity and treatment selection can alter the dominant clone, so a current accessible lesion may be more informative than an old primary specimen.
07Common pitfallsFrequent interpretation and management errors.
- 01
Ordering HER2 only after ER and PR results return creates avoidable delay and contradicts NICE simultaneous initial assessment.
- 02
Calling an equivocal HER2 result positive can expose a patient to ineffective treatment and cardiac risk before the laboratory algorithm is complete.
- 03
Assuming triple-negative disease proves a germline BRCA variant confuses tumour phenotype with constitutional genetic status.
- 04
Using ER positivity alone to omit staging, surgery or chemotherapy assessment ignores tumour burden and absolute recurrence risk.